JONATHAN FLANAGAN to Hydroxyurea
This is a "connection" page, showing publications JONATHAN FLANAGAN has written about Hydroxyurea.
Connection Strength
1.670
-
Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One. 2014; 9(10):e110740.
Score: 0.446
-
Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol. 2012 Apr; 157(2):240-8.
Score: 0.371
-
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res. 2010 Apr 30; 698(1-2):38-42.
Score: 0.324
-
The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil. Blood Cells Mol Dis. 2016 11; 62:32-37.
Score: 0.128
-
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol. 2013 Jul; 88(7):571-6.
Score: 0.101
-
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer. 2012 Aug; 59(2):254-7.
Score: 0.090
-
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03; 118(18):4985-91.
Score: 0.090
-
Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011 Jul; 154(1):134-40.
Score: 0.088
-
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS One. 2016; 11(10):e0164364.
Score: 0.032